Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | MMP8 | P22894 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 2/20 | 0.49 |
| ▸ | EDNRA | P25101 | 2/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.47 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.47 |
| ▸ | REN | P00797 | 1/20 | 0.46 |
| ▸ | CCKBR | P32239 | 3/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23677871 | 1.00 | MMP9 (0.50) | MMP9MMP8IDO1EDNRAHDAC3 | |
| SCHEMBL18395551 | 0.94 | IDO1 (0.54) | MMP9MMP8IDO1HDAC3HDAC4 | |
| SCHEMBL18396320 | 0.90 | MMP9 (0.52) | MMP9MMP8IDO1EDNRAHDAC3 | |
| SCHEMBL23677903 | 0.90 | HDAC3 (0.49) | MMP9MMP8IDO1HDAC3HDAC4 | |
| SCHEMBL18407272 | 0.90 | HDAC3 (0.49) | MMP9MMP8IDO1HDAC3HDAC4 | |
| SCHEMBL18407265 | 0.89 | IDO1 (0.51) | MMP9MMP8IDO1HDAC3HDAC4 | |
| SCHEMBL23677827 | 0.89 | IDO1 (0.51) | MMP9MMP8IDO1HDAC3HDAC4 | |
| SCHEMBL23677834 | 0.88 | HDAC3 (0.48) | MMP9MMP8IDO1HDAC3HDAC4 | |
| SCHEMBL18407270 | 0.88 | HDAC3 (0.48) | MMP9MMP8IDO1HDAC3HDAC4 | |
| SCHEMBL24445528 | 0.87 | IDO1 (0.47) | MMP9MMP8IDO1HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3613420-B1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | LUMOS PHARMA INC (US) | 2022-05-25 | — | — | EP | disclosed |
| EP-3324958-B1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | LUMOS PHARMA INC (US) | 2021-07-28 | — | — | EP | disclosed |
| US-20200283385-A1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | LUMOS PHARMA, INC. | 2020-09-10 | — | — | US | disclosed |
| US-20190248739-A1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | LUMOS PHARMA, INC. | 2019-08-15 | — | — | US | disclosed |
| US-10207990-B2 | Salts and prodrugs of 1-methyl-D-tryptophan | NEWLINK GENETICS CORPORATION (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180134658-A1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | LUMOS PHARMA, INC. | 2018-05-17 | — | — | US | disclosed |
| US-20180134658-A1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | LUMOS PHARMA, INC. | 2018-05-17 | — | — | US | disclosed |
| US-9732035-B2 | Salts and prodrugs of 1-methyl-D-tryptophan | NEWLINK GENETICS CORPORATION (US) | 2017-08-15 | — | — | US | disclosed |
| US-9732035-B2 | Salts and prodrugs of 1-methyl-D-tryptophan | NEWLINK GENETICS CORPORATION (US) | 2017-08-15 | — | — | US | disclosed |
| US-20170022157-A1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | LUMOS PHARMA, INC. | 2017-01-26 | — | — | US | disclosed |
| US-20170022157-A1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | LUMOS PHARMA, INC. | 2017-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190248739-A1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | IDO1, IDO2, INMT | MMP9 375/4885MMP8 629/4885IDO1 1/4885 |
| US-10207990-B2 | Salts and prodrugs of 1-methyl-D-tryptophan | IDO1, IDO2, INMT | MMP9 375/4885MMP8 629/4885IDO1 1/4885 |
| US-20200283385-A1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | IDO1, IDO2, INMT | MMP9 375/4885MMP8 629/4885IDO1 1/4885 |
| US-20170022157-A1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | IDO1, IDO2, INMT | MMP9 375/4885MMP8 629/4885IDO1 1/4885 |
| US-20180134658-A1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | IDO1, IDO2, INMT | MMP9 375/4885MMP8 629/4885IDO1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.